Angiotensin Peptides and Their Role in SARS-CoV-2 Spike Protein–Host Receptor Binding

Study Background and Research Question

The COVID-19 pandemic, caused by SARS-CoV-2, has accelerated the need to understand virus–host interactions at a molecular level. Central to viral entry is the spike (S) protein, which binds to multiple host cell receptors, most notably angiotensin-converting enzyme 2 (ACE2). However, alternative receptors such as AXL and neuropilin-1 (NRP1) also facilitate infection, especially in cells with low ACE2 expression. The renin-angiotensin system (RAS), long recognized for its role in blood pressure regulation and cardiovascular homeostasis, produces a range of angiotensin peptide fragments through enzymatic cleavage. Whether these peptides modify SARS-CoV-2’s receptor engagement has remained unclear, especially considering their established roles as vasoconstrictor peptides and modulators of aldosterone release. The reference study (Oliveira et al., 2025) addresses this gap by investigating how different angiotensin fragments influence spike protein binding to host receptors.

Key Innovation from the Reference Study

The major innovation of Oliveira et al. (2025) lies in demonstrating that specific angiotensin peptides can enhance the binding affinity of the SARS-CoV-2 spike protein to the AXL receptor, and to a lesser extent, to ACE2 and NRP1. Notably, the study finds that particular shorter angiotensin fragments—including those with sequences analogous to Angiotensin 1/2 (2-7)—are even more potent enhancers of spike–AXL binding than the canonical Angiotensin II (1–8) peptide. This reveals a previously underappreciated molecular cross-talk between RAS-derived peptides and viral pathogenesis mechanisms, with implications for both cardiovascular and infectious disease research.

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to quantify the interaction between the SARS-CoV-2 spike protein and its host cell receptors in the presence of various angiotensin peptides. The experimental design included:

• A panel of angiotensin peptides, ranging from the full-length Angiotensin I (1–10) to shorter fragments such as Angiotensin II (1–8), Angiotensin (1–7), Angiotensin (2–7), and others.
• Systematic C-terminal and N-terminal truncations to map the minimal sequence required for enhancement of spike–AXL binding.
• Investigation of specific amino acid modifications, such as tyrosine phosphorylation or substitution, to elucidate structure–function relationships.
• Direct comparison of spike protein binding to ACE2, AXL, and NRP1 in the presence of each peptide.

Through this comparative approach, the study aimed to dissect which structural features of angiotensin peptides are responsible for modulating spike–receptor interactions.

Protocol Parameters

• Peptide preparation: All angiotensin peptides were solubilized to working concentrations consistent with their reported solubility profiles (e.g., Angiotensin 1/2 (2-7): water ≥46.6 mg/mL, DMSO ≥78.4 mg/mL, as reported in the product information).
• Binding assay conditions: Receptors (AXL, ACE2, NRP1) were immobilized, and spike protein was incubated with or without peptide fragments prior to quantification via ELISA-based detection.
• Sequence comparison: Systematic truncations and modifications (e.g., ARG-VAL-TYR-ILE-HIS-PRO for Angiotensin 1/2 (2-7)) enabled mapping of activity to specific residues.
• Data interpretation: Fold-change in binding was calculated relative to peptide-free controls, with statistical significance assessed using standard biochemical approaches.

Core Findings and Why They Matter

A pivotal finding is that shorter angiotensin peptides—especially those with N-terminal deletions—markedly increased spike–AXL binding. In particular, Angiotensin IV (3–8) produced a 2.7-fold increase, while Angiotensin (2–7) also showed enhanced activity compared to the parent Angiotensin II. In contrast, the full-length Angiotensin I (1–10) had no such effect. The study also found that specific chemical modifications, such as tyrosine phosphorylation or substitution (at position 4), further amplified spike–receptor interactions (Oliveira et al., 2025).

Notably, the enhancement effect was most pronounced for the AXL receptor, a key spike protein co-receptor in respiratory tissues with low ACE2 expression, but was also detectable for ACE2 and NRP1 in certain peptide contexts. These results suggest that angiotensin peptides may exacerbate SARS-CoV-2 infectivity by facilitating alternative routes of entry, particularly in tissues where the classical ACE2 pathway is less active. This mechanism may partially explain differential tissue tropism and disease severity observed in COVID-19 patients with dysregulated RAS activity.

Comparison with Existing Internal Articles

Recent internal literature has explored the dual role of peptides such as Angiotensin 1/2 (2-7) in both cardiovascular and viral pathogenesis research. For example, "Angiotensin 1/2 (2-7): Precision Tool for Translational RAS Research" synthesizes mechanistic insights into how this peptide fragment supports advanced blood pressure and virology models, referencing early evidence for its role in spike–AXL binding. Meanwhile, "Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressure and Viral Pathogenesis Research" highlights the experimental reproducibility and solubility of validated ARG-VAL-TYR-ILE-HIS-PRO fragments, including their use in dissecting the renin-angiotensin signaling pathway.

The current reference study builds on these internal perspectives by providing direct experimental evidence and quantitative binding data, thereby strengthening the rationale for using Angiotensin 1/2 (2-7) in dual-domain research. The focus on sequence specificity and receptor selectivity complements prior mechanistic analyses and protocol guidance from internal sources.

Limitations and Transferability

While the study offers robust biochemical data, several limitations should be noted. First, the results were obtained in vitro using immobilized receptor and peptide systems; the physiological relevance of these enhancements in vivo—where peptide concentrations and tissue expression of receptors may vary—remains to be validated. Second, the study does not address downstream signaling events or infection outcomes in cellular or animal models. Third, modifications such as tyrosine phosphorylation, while informative mechanistically, may not reflect the predominant forms of angiotensin peptides in circulation. As such, transferability to clinical or in vivo settings should be approached with caution.

Why this cross-domain matters, maturity, and limitations

This study exemplifies the emerging bridge between cardiovascular research (focused on RAS peptides and blood pressure regulation) and infectious disease models (concerned with viral entry mechanisms). By identifying angiotensin peptide fragments as enhancers of SARS-CoV-2 spike–AXL binding, the work provides a molecular rationale for investigating RAS modulation as a factor in COVID-19 susceptibility and progression. However, the translational maturity is still at the preclinical stage. Additional in vivo and patient-based studies are needed to confirm whether these peptide-mediated effects impact actual infection dynamics or disease outcomes. Until then, the findings primarily inform mechanistic research and experimental modeling.

Research Support Resources

For researchers aiming to reproduce or extend these findings, Angiotensin 1/2 (2-7) (SKU A1050) is available as a high-purity, well-characterized peptide fragment suitable for binding and signaling assays. Its robust solubility and detailed documentation support a range of experimental protocols, including those outlined above. As demonstrated in both the reference study and supporting internal analyses, utilizing validated peptides such as Angiotensin 1/2 (2-7) can facilitate cross-domain investigations into the renin-angiotensin system and its intersection with viral pathogenesis.